Thomson Reuters Makes Disease Briefing on Influenza Covering H1N1 (Swine Flu) Publicly Available

    Free Access Given to Support the Global R&D and Healthcare Community

    PHILADELPHIA and LONDON, May 20 /PRNewswire/ -- In support of the efforts
of the global healthcare community working to prevent and address outbreaks
such as the current Influenza A (H1N1) flu outbreak, the Healthcare and
Science business of Thomson Reuters, the world's leading source of intelligent
information for businesses and professionals, today announced the free
availability of its Disease Briefing on Influenza taken directly from the
wealth of information and knowledge in Prous Science Integrity(R).

    The daily briefing can be downloaded from, and provides information on
Influenza A (H1N1) including:

    --  Development pipeline for related drugs and vaccines
    --  Number of laboratory confirmed cases
    --  International response to the pandemic
    --  Other critical information resources

    The information provided in this disease briefing uses a drug R&D
approach designed for life sciences researchers, versus the medical or
epidemiological approaches found elsewhere, and focuses on drugs and
vaccinations that are currently in the development pipeline or on the market.

    Disease Briefings are dynamic executive summaries of the current status
and future trends in drug therapy for a specific disease or disorder. They
provide key facts on the disease -- such as risk factors, prevalence and
incidence, morbidity and mortality figures, cost -- along with a structured,
scientific approach to the drug R&D-related aspects of diagnosis, prevention
and treatment.

    "Disease Briefings utilize a scientific viewpoint to describing vaccines
and drug therapies that are currently under development. This approach
accelerates the understanding of the disease and hypotheses to direct new
research," said Jon Brett-Harris, EVP Life Sciences, Thomson Reuters. "It is
our hope that making this data freely available will aid researchers and
investigators who are responding to this challenge."

    The Prous Science Integrity drug discovery and development portal
includes 107 Disease Briefings on diseases and disorders ranging from Acne to
Cancer to West Nile Fever. The Disease Briefings are fully integrated into
Prous Science Integrity's suite of scientific information and tools covering
the biology, chemistry and pharmacology of drug discovery and development. In
Prous Science Integrity, users can link from a Disease Briefing to display the
chemical structures and synthesis of the compounds in development to
information on the biology of the corresponding drug targets -- along with
results from preclinical and clinical studies on these compounds.

    About Prous Science Integrity

    Prous Science Integrity is a unique knowledge solution designed to
empower discovery activities right where this is most needed -- at the bench.
The Prous Science Integrity portal integrates biological, chemical and
pharmacological data on more than 300,000 compounds with demonstrated
biological activity. For more information, go to

    About Thomson Reuters

    Thomson Reuters is the world's leading source of intelligent information
for businesses and professionals.  We combine industry expertise with
innovative technology to deliver critical information to leading decision
makers in the financial, legal, tax and accounting, scientific, healthcare and
media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs more than 50,000 people in 93 countries. For more
information, go to


For further information:

For further information: Allison Hagan, Healthcare and Science, of
Thomson Reuters, +1-215-823-1881, Web Site:

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890